<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423344</url>
  </required_header>
  <id_info>
    <org_study_id>HFE-05-02</org_study_id>
    <secondary_id>Danish Ethics comittee</secondary_id>
    <nct_id>NCT01423344</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the Serum Free Light Chain Analysis</brief_title>
  <official_title>Assessment of the Value of the Free Kappa and Free Lambda Light Chain Assay in Clinical Evaluation of Response to Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charlotte Toftmann Hansen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: in patients with multiple myeloma there is a raised level of a protein, named&#xD;
      M-protein. This M-protein is normally used to monitor disease status and evaluate response to&#xD;
      treatment, as a decrease in M-protein is taken as evidence of therapeutic efficacy. However,&#xD;
      the M-protein has a long half life in serum, approximately three weeks, which tend to be a&#xD;
      practical problem, since the investigators can first determine hereafter if the treatment is&#xD;
      effective.&#xD;
&#xD;
      A new assay has the possibility only to measure part of this protein, namely &quot;the light&#xD;
      chains&quot;, which also is measured in a blood sample. The half life of these light chains is&#xD;
      much shorter, namely 2-6 hours. In theory, this means a more rapid measure of the effect of a&#xD;
      given treatment, thereby being able to determine earlier if the treatment should continue or&#xD;
      changed to another strategy.&#xD;
&#xD;
      Purpose: the purpose of this study is to evaluate the clinical value of the use of the serum&#xD;
      free light chain (sFLC) assay in comparison to the M-protein in monitoring patients under&#xD;
      treatment for multiple myeloma.&#xD;
&#xD;
      Method: the investigators measure sFLC in patients receiving there 1st treatment, either at&#xD;
      the time of diagnosis or in the relapse setting. sFLC is measured on a regular basis, and the&#xD;
      results are compared to the M-protein.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to 50% reduction in the concentration of the abnormal serum free light chain compared to 50% reduction in M-protein</measure>
    <time_frame>1, 2, 3, 4 and 5 days, 2, 3 and 6 weeks after therapy,</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Myeloma</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed patients with multiple myeloma, with medical needs and known patients with&#xD;
        multiple myeloma at there 1st relapse and medical needs&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of multiple myeloma&#xD;
&#xD;
          -  abnormal serum free light chains&#xD;
&#xD;
          -  medical needs of anti-myeloma therapy&#xD;
&#xD;
          -  receiving standard anti-myeloma therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  dialysis&#xD;
&#xD;
          -  normal serum free light chains&#xD;
&#xD;
          -  dementia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte T Hansen, Fellow</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Haematology, research unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte T Hansen, Fellow</last_name>
    <phone>0045 24428085</phone>
    <email>charlotte.toftmann.hansen@ouh.regionsyddanmark.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Niels Abildgaard, Prof. dr.med</last_name>
    <phone>0045 65411637</phone>
    <email>niels.abildgaard@ouh.regionsyddanmark.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Haematology, research unit</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte T Hansen, Fellow</last_name>
      <phone>0045 24428085</phone>
      <email>charlotte.toftmann.hansen@ouh.regionsyddanmark.dk</email>
    </contact>
    <investigator>
      <last_name>Charlotte T Hansen, Fellow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>August 24, 2011</study_first_submitted>
  <study_first_submitted_qc>August 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2011</study_first_posted>
  <last_update_submitted>August 24, 2011</last_update_submitted>
  <last_update_submitted_qc>August 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Charlotte Toftmann Hansen</investigator_full_name>
    <investigator_title>Fellow, ph.d-stud</investigator_title>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>Free light chains</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

